Update on staging controversies for locally advanced renal cell carcinoma

Expert Review of Anticancer Therapy

Volumn 7, Issue 7, 2007, Pages 909-914

  Margulis, Vitaly ^a   Wood, Christopher G ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBONATE DEHYDRATASE IX; GELSOLIN; KI 67 ANTIGEN; PROTEIN P53; VIMENTIN;

ACCURACY; ADRENAL METASTASIS; ADVANCED CANCER; CANCER INVASION; CANCER STAGING; CANCER SURVIVAL; CLINICAL FEATURE; DISEASE MARKER; EDITORIAL; HIGH RISK PATIENT; HISTOPATHOLOGY; HUMAN; INTERMETHOD COMPARISON; KIDNEY CARCINOMA; KIDNEY VEIN THROMBOSIS; LYMPH NODE METASTASIS; NEPHRECTOMY; POSTOPERATIVE PERIOD; PREDICTION; PROGNOSIS; PROTEIN EXPRESSION; RISK ASSESSMENT; SURVIVAL RATE; THROMBECTOMY; TREATMENT OUTCOME; TUMOR LOCALIZATION; TUMOR RECURRENCE; TUMOR THROMBUS; TUMOR VOLUME;

CARCINOMA, RENAL CELL; HUMANS; KIDNEY NEOPLASMS; NEOPLASM STAGING; PROGNOSIS;

EID: 34547503816     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/14737140.7.7.909     Document Type: Editorial

References (40)

1. AJCC Cancer Staging Manual (6th Edition). Greene FL, Page DL, Fleming ID et al. (Eds). Springer-Verlag, NY, USA (2002).
2. Motzer RJ, Bacik J, Schwartz LH et al. Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma. J. Clin. Oncol. 22, 454-463 (2004).
3. Lam JS, Belldegrun AS, Pantuck AJ. Long-term outcomes of the surgical management of renal cell carcinoma. World J. Urol. 24, 255-266 (2006).
4. Gospodarowicz MK, Miller D, Groome PA et al. The process for continuous improvement of the TNM classification. Cancer 100, 1-5 (2004).
5. Leibovich BC, Cheville JC, Lohse CM et al. Cancer specific survival for patients with pT3 renal cell carcinoma - can the 2002 primary tumor classification be improved J. Urol. 173, 716-719 (2005).
6. Thompson RH, Cheville JC, Lohse CM et al. Reclassification of patients with pT3 and pT4 renal cell carcinoma improves prognostic accuracy. Cancer 104, 53-60 (2005).
7. Ficarra V, Novara G, Iafrate M et al. Proposal for reclassification of the TNM staging system in patients with locally advanced (pT3-4) renal cell carcinoma according to the cancer-related outcome. Eur. Urol. 51(3), 722-729 (2006).
8. Margulis V, Tamboli P, Matin SF et al. Redefining pT3 renal cell carcinoma in the modern era: a proposal for a revision of the current TNM primary tumor classification system. Cancer 109(12), 2439-2444 (2007).
9. Murphy MJ, Chartier M, Beauchemin C et al. Cutaneous metastasis of renal cell carcinoma with Zellballen-like inflammatory reaction pattern on immunohistochemical studies. Appl. Immunohistochem. Mol. Morphol. 14, 178-180 (2006).
10. Siemer S, Lehmann J, Loch A et al. Current TNM classification of renal cell carcinoma evaluated: revising stage T3a. J. Urol. 173, 33-37 (2005).
11. Gilbert SM, Murphy AM, Katz AE et al. Reevaluation of TNM staging of renal cortical tumors: recurrence and survival for T1N0M0 and T3aN0M0 tumors are equivalent. Urology 68, 287-291 (2006).
12. Lam JS, Klatte T, Patard JJ et al. Prognostic relevance of tumour size in T3a renal cell carcinoma: a multicentre experience. Eur. Urol. 52(1), 155-162 (2007).
13. Kletscher BA, Qian J, Bostwick DG et al. Prospective analysis of the incidence of ipsilateral adrenal metastasis in localized renal cell carcinoma. J. Urol. 155, 1844-1846 (1996).
14. Shalev M, Cipolla B, Guille F et al. Is ipsilateral adrenalectomy a necessary component of radical nephrectomy J. Urol. 153, 1415-1417 (1995).
15. Tsui KH, Shvarts O, Barbaric Z et al. Is adrenalectomy a necessary component of radical nephrectomy UCLA experience with 511 radical nephrectomies. J. Urol. 163, 437-441 (2000).
16. Kuczyk M, Munch T, Machtens S et al. The need for routine adrenalectomy during surgical treatment for renal cell cancer: the Hannover experience. Br. J. Urol. Int. 89, 517-522 (2002).
17. Siemer S, Lehmann J, Kamradt J et al. Adrenal metastases in 1635 patients with renal cell carcinoma: outcome and indication for adrenalectomy. J. Urol. 171, 2155-2159; discussion 2159 (2004).
18. Han KR, Bui MH, Pantuck AJ et al. TNM T3a renal cell carcinoma: adrenal gland involvement is not the same as renal fat invasion. J. Urol. 169, 899-903; discussion 903-904 (2003).
19. Thompson RH, Leibovich BC, Cheville JC et al. Should direct ipsilateral adrenal invasion from renal cell carcinoma be classified as pT3a J. Urol. 173, 918-921 (2005).
20. Satyapal KS. Classification of the drainage patterns of the renal veins. J. Anat. 186(Pt 2), 329-333 (1995).
21. Beckwith JB. National Wilms Tumor Study: an update for pathologists. Pediatr. Dev. Pathol. 1, 79-84 (1998).
22. Bonsib SM. The renal sinus is the principal invasive pathway: a prospective study of 100 renal cell carcinomas. Am. J. Surg. Pathol. 28, 1594-1600 (2004).
23. Thompson RH, Leibovich BC, Cheville JC et al. Is renal sinus fat invasion the same as perinephric fat invasion for pT3a renal cell carcinoma? J. Urol. 174, 1218-1221 (2005).
24. Margulis V, Tamboli P, Matin SF et al. pT3a renal cell carcinoma: does location of extrarenal extension impact patient outcome? J. Urol. (2007) (Epub ahead of print).
25. Zisman A, Wieder JA, Pantuck AJ et al. Renal cell carcinoma with tumor thrombus extension: biology, role of nephrectomy and response to immunotherapy. J. Urol. 169, 909-916 (2003).
26. Blute ML, Leibovich BC, Lohse CM et al. The Mayo Clinic experience with surgical management, complications and outcome for patients with renal cell carcinoma and venous tumour thrombus. Br. J. Urol. Int. 94, 33-41 (2004).
27. Parekh DJ, Cookson MS, Chapman W et al. Renal cell carcinoma with renal vein and inferior vena caval involvement: clinicopathological features, surgical techniques and outcomes. J. Urol. 173, 1897-1902 (2005).
28. Hatcher PA, Anderson EE, Paulson DF et al. Surgical management and prognosis of renal cell carcinoma invading the vena cava. J. Urol. 145, 20-23; discussion 23-24 (1991).
29. Ljungberg B, Stenling R, Osterdahl B et al. Vein invasion in renal cell carcinoma: impact on metastatic behavior and survival. J. Urol. 154, 1681-1684 (1995).
30. Kuczyk MA, Bokemeyer C, Kohn G et al. Prognostic relevance of intracaval neoplastic extension for patients with renal cell cancer. Br. J. Urol. 80, 18-24 (1997).
31. Kim HL, Zisman A, Han KR et al. Prognostic significance of venous thrombus in renal cell carcinoma. Are renal vein and inferior vena cava involvement different? J. Urol. 171, 588-591 (2004).
32. Moinzadeh A, Libertino JA. Prognostic significance of tumor thrombus level in patients with renal cell carcinoma and venous tumor thrombus extension. Is all T3b the same? J. Urol. 171, 598-601 (2004).
33. Zisman A, Pantuck AJ, Wieder J et al. Risk group assessment and clinical outcome algorithm to predict the natural history of patients with surgically resected renal cell carcinoma. J. Clin. Oncol. 20, 4559-4566 (2002).
34. Patard JJ, Kim HL, Lam JS et al. Use of the University of California Los Angeles integrated staging system to predict survival in renal cell carcinoma: an international multicenter study. J. Clin. Oncol. 22, 3316-3322 (2004).
35. Frank I, Blute ML, Cheville JC et al. An outcome prediction model for patients with clear cell renal cell carcinoma treated with radical nephrectomy based on tumor stage, size, grade and necrosis: the SSIGN score. J. Urol. 168, 2395-2400 (2002).
36. Ficarra V, Martignoni G, Lohse C et al. External validation of the Mayo Clinic stage, size, grade and necrosis (SSIGN) score to predict cancer specific survival using a European series of conventional renal cell carcinoma. J. Urol. 175, 1235-1239 (2006).
37. Kattan MW, Reuter V, Motzer RJ et al. A postoperative prognostic nomogram for renal cell carcinoma. J. Urol. 166, 63-67 (2001).
38. Yaycioglu O, Roberts WW, Chan T et al. Prognostic assessment of nonmetastatic renal cell carcinoma: a clinically based model. Urology 58, 141-145 (2001).
39. Cindolo L, de la Taille A, Messina G et al. A preoperative clinical prognostic model for non-metastatic renal cell carcinoma. Br. J. Urol. Int. 92, 901-905 (2003).
40. Lam JS, Leppert JT, Figlin RA, Belldegrun AS. Role of molecular markers in the diagnosis and therapy of renal cell carcinoma. Urology 66, 1-9 (2005).